



CE Marked Material
QCRHBeQC1 - Anti-HBe Quality Control Serum Sample 1
NIBSC code: 13/B629-xxx
Instructions for use
(Version 7.0, Dated 28/04/2022)

This material is an 'Annex II List A' IVD and complies with the requirements of the "EU in vitro diagnostic medical device directive 98/79/EC"

1. INTENDED USE

This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

Anti-HBe QC1 is intended for use in the internal laboratory quality control of immunoassays that detect antibodies to hepatitis B e antigen. The anti-HBe QC1 should be included in each run as part of a continuing quality control programme to monitor the performance of the assay. Data obtained with the anti-HBe QC1 can be used to construct quality control charts that can be visually monitored each time the assay is run to check for consistency of performance of the assay. Examples of how these charts are constructed and used have been described elsewhere1. Anti-HBe QC1 is NOT INTENDED TO BE USED TO COMPARE THE SENSITIVITY OF PARTICULAR ASSAYS.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

Table 1 gives a summary of the results obtained for anti-HBe QC1 13/B629 These results are intended only as a guide to the approximate levels of reactivity to be expected, and may not be exactly reproduced in other laboratories. In each case, at a minimum, three samples of anti-HIBe QC1 were tested on two separate occasions. The results are expressed as the ratio of mean optical density or other measurement of the anti-HBe response of the QC1 sample, to the kit manufacturer's calculated cut-off.

4. CONTENTS

Country of origin of biological material: United Kingdom.

Ready-to-use reagent

REF QCRHBeQC1 1x7mL Blood tubes

Defibrinated Plasma 4mL

Bronidox® (Sigma-Aldrich) 0.05% (w/v)

5. STORAGE

- o Reagents are to be kept at 2-8°C upon receipt
- o Reagents may be stored at 2-8°C until use by date
- o Reagents should be divided into measured sub-aliquots and stored below -20°C to avoid freeze/thaw cycles.

- o When thawed for use, store at 2-8°C. Once thawed, use within one month and do not refreeze
- o Ensure all containers are properly sealed to avoid drying out of the reagent
- o Avoid microbial contamination of this product as this may alter product performance
- o Avoid excessively high temperatures or humidity

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

- 1. Use of this reagent is to be restricted to trained laboratory staff only
- 2. Use suitable (latex/nitrile) gloves and eye/skin protection
- 3. Include reagent as a normal sample in routine work list
- 4. Allow reagent to reach room temperature before use
- 5. Plot reagent result to monitor performance

The Result Reporting System (RRS) has been developed by the National Institute for Biological Standards and Control (NIBSC) for the data monitoring of its serology and NAT quality control (QC) reagents. These include the Quality Control Reagent Unit (QCRU) and Clinical Virology Network (CVN) reagents. The system has been successfully running for serology assays for several years collecting thousands of data points a year. The system has recently been developed to accept data for Nucleic Acid-based Technologies (NAT) reagents and associated assays.

https://www.nibsc.org/products/rrs.aspx

8. STABILITY (Add or amend as necessary)

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

Stability study analysis has been performed on this reagent to assess stability. The expiry date is shown on the label.

9. REFERENCES

1. Levey, S. and Jennings, E.R. (1950) The use of control charts in clinical laboratories. Am.J.Clin.Pathol. 20, 1059-1066

10. ACKNOWLEDGEMENTS

EC REP Advena Ltd. Tower Business Centre, 2nd Floor, Swatar, BKR 4013, Malta

11. FURTHER INFORMATION

Further information can be obtained as follows;

This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/

JCTLM Higher order reference materials:

http://www.bipm.org/en/committees/jc/jctlm/

Derivation of International Units:

http://www.nibsc.org/standardisation/international_standards.aspx

Ordering standards from NIBSC:

http://www.nibsc.org/products/ordering.aspx







NIBSC Confidence in Biological Medicines

NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET (Add or amend as necessary)

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

| (EC) No 1272/2008: Not applicable or not classified | | | | |
|---|----------------|---------------------------------|----------------------|--|
| Physical and Chemical properties | | | | |
| Physical appearance: | | Corrosive: | No | |
| Liquid | | | | |
| Stable: Yes | | Oxidising: | No | |
| Hygroscopic: No | | Irritant: | No | |
| Flammable: No | | Handling:See | e caution, Section 2 | |
| Other (specify): | | | | |
| Toxicological properties | | | | |
| Effects of inhalation: Not | | established, a | void inhalation | |
| Effects of ingestion: Not | | established, avoid ingestion | | |
| Effects of skin | Not e | established, avoid contact with | | |
| absorption: | skin | | | |
| Suggested First Aid | | | | |
| Inhalation: Seek medical advice | | | | |
| Ingestion: Seek medical advice | | | | |
| Contact with Wash with copious amounts of water. Seek | | | | |
| eyes: medic | nedical advice | | | |
| Contact with skin: Wash thoroughly with water. | | | | |
| Action on Spillage and Method of Disposal | | | | |
| Spillage of ampoule contents should be taken up with absorbent | | | | |
| material wetted with an appropriate disinfectant. Rinse area with | | | | |
| an appropriate disinfectant followed by water. | | | | |

15. LIABILITY AND LOSS

biological waste.

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Absorbent materials used to treat spillage should be treated as

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freezedrying.

Net weight: 4 g

Toxicity Statement: Toxicity not assessed

Veterinary certificate or other statement if applicable.

Attached: No







1:



Results obtained for **Anti-HBe QC1** (Lot Number **13/B629**) using the following EIA kits.

| FIA KIT | Mathad Outions | Test to Cut-of | Test to Cut-off Ratio | |
|----------------------------------|--------------------|----------------|-----------------------|--|
| EIA KIT | Method Options | Mean | SD (n-1) | |
| | | | | |
| Dia.Pro HBe Ab | Standard Protocol | 4.1 | 0.5 | |
| Manufacturer: Dia.Pro | | | | |
| Catalogue Number: HBE.CE | | | | |
| Lot Number: C5A3T12/4 | | | | |
| | | | | |
| Architect Anti-HBe | Automated Protocol | 0.1 | N/A | |
| Manufacturer: Abbott Diagnostics | | | | |
| Catalogue Number: 6C34 | | | | |
| Lot Number: 23380LI00 | | | | |

